SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specialising in cannabinoid-based medicines, in collaboration with Lusófona University, the largest Portuguese private university and the main institution of Grupo Lusófona, has published a groundbreaking peer-reviewed paper in Pharmaceuticals journal titled ‘Process Development for GMP-Grade Full Extract Cannabis Oil: Towards Standardised Medicinal Use.’
The study validates SOMAÍ’s patent-pending process for producing Full-Spectrum Extract Cannabis Oil (FECO), offering new scientific evidence that bridges pharmaceutical precision with consistent, patient-friendly formulations.
Key findings from the research include:
- Standardised Full-Spectrum Composition – SOMAÍ’s process of terpene extraction, deep-cooled ethanol extraction and purification preserves the native cannabinoid and terpene profile of the plant throughout the production process.
- Enhanced Patient Experience – Sensory analysis revealed higher acceptance ratings for SOMAÍ’s purified FECO versus crude extracts or competing products. Improvements in taste, color, and overall appearance make these preparations more tolerable and effective for patients.
- Scientific Differentiation – The research shows that the terpene fingerprint from the flower is remarkably preserved and can be controlled for reintroduction—emphasising that terpene formulation is a science, not guesswork.
“This paper underscores SOMAÍ’s scientific leadership in the cannabis pharmaceutical industry,” said Michael Sassano, Founder and Interim CEO of SOMAÍ.
“Our study demonstrates that full-spectrum cannabis formulations can be scientifically structured, reproducible, and pharmaceutically precise—dispelling the misconception that full-spectrum must mean uncontrolled or inconsistent.”
“This research is a step forward in establishing scientific rigor within the medical cannabis field,” said Professor Maria do Céu Costa of Lusófona University.
“Our findings show that with the right methodology, it is possible to preserve the integrity of the plant while achieving consistency, safety, and improved patient acceptance. It’s a meaningful contribution to both science and therapeutic innovation.”
Unlike unrefined crude extracts or formulations created without standardised methodology, SOMAÍ’s approach is rooted in pharmaceutical science and controlled processes. This ensures a consistent cannabinoid and terpene profile that meets rigorous regulatory requirements while enhancing both the therapeutic efficacy and patient experience.
Read the full text of the publication online at MDPI: https://www.mdpi.com/1999-4923/17/7/848
